2015 Press Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
04/30/15Seattle Genetics Reports First Quarter 2015 Financial Results
-Total First Quarter 2015 Revenues of $82.2 Million, Including $48.9 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -Supplemental Biologics License Application (BLA) Filed by FDA with Priority Review for Phase 3 AETHERA Trial; PDUFA Date August 18, 2015- -Completed Special Protocol Assessment (SPA) Amendments for ECHELON-1 and ECHELON-2 Phase 3 Confirmatory Trials- -Conference Call Today at 4:30 p.m. ... 
Printer Friendly Version
04/28/15Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 28, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. 40th Annual Deutsche Bank Health Care Conference Wednesday, May 6, 9:20 a.m. Eastern Time, Boston ... 
Printer Friendly Version
04/20/15FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the AETHERA Setting for the Post-Transplant Consolidation Treatment of Hodgkin Lymphoma Patients at High Risk of Relapse
-PDUFA Action Date August 18, 2015- -Submission of Supplemental BLA Based on Positive Phase 3 AETHERA Clinical Trial Results Recently Published in The Lancet- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 20, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for ADCETRIS (brentuximab vedotin) in the AETH... 
Printer Friendly Version
04/16/15Seattle Genetics Highlights Broad Presence at the American Association for Cancer Research (AACR) Annual Meeting
-Multiple Data Presentations Support Antibody-Drug Conjugate (ADC) Program Development Plans and Highlight Technology Advances- -SEA-CD40 Immuno-Oncology Preclinical Data Show Potent Activation of Antigen Presenting Cells- -ADCETRIS® (Brentuximab Vedotin) Shown to Induce Immunogenic Cell Death in Preclinical Studies; Combination Clinical Trials Planned with Nivolumab- -Senior Management to Present in Multiple Sessions on Ce... 
Printer Friendly Version
04/13/15Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2015 Financial Results on April 30, 2015
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 13, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2015 financial results on Thursday, April 30 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thu... 
Printer Friendly Version
02/25/15Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 25, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Cowen and Company 35th Annual Health Care Conference Tuesday, March 3, 8:40 a.m. Eastern Tim... 
Printer Friendly Version
02/18/15Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 18, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 AETHERA trial of ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at high risk of relapse. A... 
Printer Friendly Version
02/17/15Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors
-SEA-CD40 Utilizes Sugar-Engineered Antibody Technology Designed to Target CD40 and Stimulate the Immune System- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 17, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1 clinical trial of SEA-CD40 for multiple types of advanced solid tumors. SEA-CD40 is a novel investigational immuno-oncology agent targeted to CD40, a widely expressed stimulatory receptor found on ant... 
Printer Friendly Version
02/10/15Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results
-Total 2014 Revenues of $286.8 Million, Including $178.2 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Phase 3 AETHERA Supplemental BLA Submission Planned in First Quarter 2015- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 10, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December... 
Printer Friendly Version
02/05/15Seattle Genetics to Present at Leerink Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 5, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the Leerink Global Healthcare Conference on Thursday, February 12, at 11:35 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version
01/21/15Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 21, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2014 financial results on Tuesday, February 10, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE a... 
Printer Friendly Version
01/12/15Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
BOTHELL, Wash. & NEW YORK--(BUSINESS WIRE)--Jan. 12, 2015-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 ... 
Printer Friendly Version
01/06/15Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 6, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, at 11:30 a.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version